WEBVTT
Kind: captions
Language: en

1
00:00:00.350 --> 00:00:02.481
A gene therapy candidate called

2
00:00:02.481 --> 00:00:04.612
ER-100 has entered human testing.

3
00:00:04.612 --> 00:00:08.447
Here is exactly what has been confirmed so far.

4
00:00:09.250 --> 00:00:12.967
ER-100 comes from the company Life Biosciences.

5
00:00:12.967 --> 00:00:15.622
Its approach is called partial

6
00:00:15.622 --> 00:00:16.685
epigenetic reprogramming.

7
00:00:17.483 --> 00:00:21.412
It uses three of the four Yamanaka factors: OCT4,

8
00:00:21.412 --> 00:00:24.468
SOX2 and KLF4. The fourth one, c-Myc,

9
00:00:24.468 --> 00:00:26.214
is deliberately left out.

10
00:00:27.017 --> 00:00:30.618
On 28 January 2026, the U.S.

11
00:00:30.618 --> 00:00:33.619
FDA cleared the Investigational New

12
00:00:33.619 --> 00:00:36.020
Drug application for ER-100.

13
00:00:36.817 --> 00:00:42.451
The first participant was dosed on 9 June 2026.

14
00:00:42.451 --> 00:00:46.207
The study is registered as NCT07290244.

15
00:00:47.017 --> 00:00:50.262
The trial enrolls two eye conditions:

16
00:00:50.262 --> 00:00:51.344
open-angle glaucoma,

17
00:00:51.344 --> 00:00:52.967
and non-arteritic anterior

18
00:00:52.967 --> 00:00:54.590
ischemic optic neuropathy.

19
00:00:55.383 --> 00:00:57.258
This is a Phase 1 study.

20
00:00:57.258 --> 00:00:59.132
Phase 1 asks one question first:

21
00:00:59.132 --> 00:01:00.694
is it safe in people.

22
00:01:00.694 --> 00:01:02.880
It is not a measurement of benefit.

23
00:01:03.683 --> 00:01:05.251
ER-100 is not approved,

24
00:01:05.251 --> 00:01:07.211
is not available for purchase,

25
00:01:07.211 --> 00:01:09.955
and is not offered at this clinic.

26
00:01:09.955 --> 00:01:12.307
This is an industry news summary,

27
00:01:12.307 --> 00:01:13.483
not medical advice.